Post-meal hyperglycaemia is associated with a negative impact on quality of life for people with diabetes
Black and ethnic minority patients underrepresented in trials for diabetes treatment
Diabetes prevalence soars to 3.8 million people in England
Diabetes drugs costing NHS nearly £1 billion per year
New intervention shows promising new prospects for the management of type 2 diabetes
A significant improvement in hyperglycaemia in patients with type 2 diabetes poorly controlled on one or more oral antidiabetic agents was seen in the first-in-human study of RevitaTM duodenal mucosal resurfacing (Revita DMR) - a new 60 minute non-surgical procedure - according to data published in the current issue of Diabetes Care.
Victoza significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes
New data shows lower rates of hypoglycaemia with Tresiba
New data for liraglutide in type 2 diabetes
Findings from a clinical trial comparing liraglutide 1.8mg (Victoza) and sitagliptin (100mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions versus continuing with sitagliptin treatment in adults with type 2 diabetes.